{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:31:11Z","timestamp":1789381871169,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014607","name":"Royal Children's Hospital Foundation","doi-asserted-by":"publisher","award":["2020-1263"],"award-info":[{"award-number":["2020-1263"]}],"id":[{"id":"10.13039\/100014607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016056","name":"Minderoo Foundation Limited","doi-asserted-by":"publisher","award":["COV-001"],"award-info":[{"award-number":["COV-001"]}],"id":[{"id":"10.13039\/501100016056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N006364\/2"],"award-info":[{"award-number":["MR\/N006364\/2"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1197117"],"award-info":[{"award-number":["GNT1197117"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV017302"],"award-info":[{"award-number":["INV017302"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P2GEP3_178155"],"award-info":[{"award-number":["P2GEP3_178155"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032048","name":"National Australia Bank Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013060","name":"European Molecular Biology Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013543","name":"European Society for Paediatric Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jinf.2025.106436","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:38:12Z","timestamp":1738870692000},"page":"106436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response"],"prefix":"10.1016","volume":"90","author":[{"given":"C.C.A.","family":"Noble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Biering-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"Pittet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Croda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dalcolmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.G.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Lynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Prat Aymerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.C.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Warris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.L.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jinf.2025.106436_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jinf.2021.04.037","article-title":"Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021","volume":"83","author":"Whitaker","year":"2021","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jinf.2025.106436_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac677","article-title":"Reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients","volume":"10","author":"Dhakal","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2025.106436_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052101","article-title":"BCG vaccination to reduce the impact of COVID-19 in healthcare workers: protocol for a randomised controlled trial (BRACE trial)","volume":"11","author":"Pittet","year":"2021","journal-title":"BMJ Open"},{"issue":"17","key":"10.1016\/j.jinf.2025.106436_bib4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1056\/NEJMoa2212616","article-title":"Randomized trial of BCG vaccine to protect against Covid-19 in health care workers","volume":"388","author":"Pittet","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jinf.2025.106436_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106245","article-title":"BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial","volume":"89","author":"Messina","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2025.106436_bib6","unstructured":"Roche Diagnostics International Ltd. Elecsys\u00ae Anti-SARS-CoV-2. Immunoassay for the qualitative detection of antibodies against SARS-CoV-2; 2020. \u3008https:\/\/diagnosticsrochecom\/content\/dam\/diagnostics\/Blueprint\/en\/pdf\/cps\/Elecsys-Anti-SARS-CoV-2-factsheet-2020-JULpdf\u3009."},{"key":"10.1016\/j.jinf.2025.106436_bib7","unstructured":"StataCorp. Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC; 2023."},{"issue":"4","key":"10.1016\/j.jinf.2025.106436_bib8","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jinf.2021.08.012","article-title":"Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals","volume":"83","author":"Allen","year":"2021","journal-title":"J Infect"},{"issue":"9","key":"10.1016\/j.jinf.2025.106436_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jinf.2025.106436_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad069","article-title":"Kinetics of the antibody response to symptomatic SARS-CoV-2 infection in vaccinated and unvaccinated individuals in the blinded phase of the mRNA-1273 COVID-19 vaccine efficacy trial","volume":"10","author":"Follmann","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2025.106436_bib11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/vaccines11071258","article-title":"COVID-19 infection, vaccination, and antibody levels: investigating correlations through a cohort study","volume":"11","author":"Kayal\u0131","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jinf.2025.106436_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.105052","article-title":"Antibody response to SARS-CoV-2 for more than one year \u2013 kinetics and persistence of detection are predominantly determined by avidity progression and test design","volume":"146","author":"Scheiblauer","year":"2022","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.jinf.2025.106436_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115659","article-title":"Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection","volume":"103","author":"Van Elslande","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2025.106436_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1026473","article-title":"Enhanced spike-specific, but attenuated nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2025.106436_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2023.105622","article-title":"Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: a prospective cohort study in non-hospitalized adults","volume":"170","author":"Prelog","year":"2024","journal-title":"J Clin Virol"},{"issue":"2","key":"10.1016\/j.jinf.2025.106436_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.02262-21","article-title":"A dual-antigen SARS-CoV-2 serological assay reflects antibody avidity","volume":"60","author":"Nakagama","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.jinf.2025.106436_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288557","article-title":"Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: a prospective longitudinal study","volume":"18","author":"Amellal","year":"2023","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jinf.2025.106436_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01231-21","article-title":"SARS-CoV-2 serologic assays dependent on dual-antigen binding demonstrate diverging kinetics relative to other antibody detection methods","volume":"59","author":"Theel","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jinf.2025.106436_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/03946320231187744","article-title":"Anti-nucleocapsid IgG antibodies in SARS-CoV-2 recovered health care workers: one year follow-up study","volume":"37","author":"Ahmad","year":"2023","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6","key":"10.1016\/j.jinf.2025.106436_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00597-22","article-title":"One-year follow-up of COVID-19 patients indicates substantial assay-dependent differences in the kinetics of SARS-CoV-2 antibodies","volume":"10","author":"Egger","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"4","key":"10.1016\/j.jinf.2025.106436_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00986-22","article-title":"Detecting waning serological response with commercial immunoassays: 18-month longitudinal follow-up of anti-SARS-CoV-2 nucleocapsid antibodies","volume":"10","author":"Nakagama","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jinf.2025.106436_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103561","article-title":"Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection","volume":"71","author":"Gallais","year":"2021","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jinf.2025.106436_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12916-022-02570-3","article-title":"Sustained seropositivity up to 20.5 months after COVID-19","volume":"20","author":"Doba\u00f1o","year":"2022","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.jinf.2025.106436_bib24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/vaccines10081189","article-title":"Humoral and cellular immunogenicity of six different vaccines against SARS-CoV-2 in adults: a comparative study in Tunisia (North Africa)","volume":"10","author":"Ben Ahmed","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.jinf.2025.106436_bib25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jmv.27420","article-title":"Evaluation of antibody response after COVID-19 vaccination of healthcare workers","volume":"94","author":"Uysal","year":"2022","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.jinf.2025.106436_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7883\/yoken.JJID.2023.061","article-title":"The long-term serological profile of CoronaVac vaccine based on comorbidities and history of SARS-CoV-2 infection in Indonesia","volume":"77","author":"Chilmi","year":"2024","journal-title":"Jpn J Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2025.106436_bib27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/infdis\/jiad320","article-title":"Differential severe acute respiratory syndrome coronavirus 2-specific humoral response in inactivated virus-vaccinated, convalescent, and breakthrough-infected subjects","volume":"228","author":"Duarte","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2025.106436_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1229045","article-title":"Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer\/BioNTech) vaccines in Chile","volume":"11","author":"D\u00edaz-Dinamarca","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.jinf.2025.106436_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijid.2021.09.060","article-title":"Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection","volume":"113","author":"Azak","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jinf.2025.106436_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103904","article-title":"Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong","volume":"77","author":"Peng","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jinf.2025.106436_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/9313267","article-title":"The key to increase immunogenicity of next-generation COVID-19 vaccines lies in the inclusion of the SARS-CoV-2 nucleocapsid protein","volume":"2024","author":"Mendoza-Ram\u00edrez","year":"2024","journal-title":"J Immunol Res"},{"issue":"11","key":"10.1016\/j.jinf.2025.106436_bib32","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.cell.2023.04.007","article-title":"The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection","volume":"186","author":"Arieta","year":"2023","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jinf.2025.106436_bib33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.2100421","article-title":"Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity","volume":"207","author":"Matchett","year":"2021","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jinf.2025.106436_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106288","article-title":"N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial","volume":"89","author":"Rabdano","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2025.106436_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188605","article-title":"OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model","volume":"14","author":"Primard","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2025.106436_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/vaccines12010100","article-title":"Safety and immunogenicity of the Convacell(\u00ae) recombinant N protein COVID-19 vaccine","volume":"12","author":"Rabdano","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jinf.2025.106436_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2023.105621","article-title":"Serological assays for differentiating natural COVID-19 infection from vaccine induced immunity","volume":"170","author":"Cheng","year":"2024","journal-title":"J Clin Virol"},{"issue":"7","key":"10.1016\/j.jinf.2025.106436_bib38","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jinf.2025.106436_bib39","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41591-024-03131-2","article-title":"SARS-CoV-2 correlates of protection from infection against variants of concern","volume":"30","author":"Sun","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jinf.2025.106436_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol Rev"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:30:12Z","timestamp":1762248612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0163445325000301"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106436","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106436"}}